Combination Targeted Therapy with Pembrolizumab and Lenvatinib in Progressive, Radioiodine-Refractory Differentiated Thyroid Cancers.

Jena D French Bryan R Haugen Francis P Worden Daniel W Bowles Andrew G Gianoukakis Bhavana Konda Ramona Dadu Eric J Sherman Shaylene McCue Nathan R Foster Yuri E Nikiforov Ticiana Della Justina Farias Paul J Norman Lori J Wirth

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2024)

Lenvatinib plus pembrolizumab may enhance the durability of lenvatinib monotherapy in lenvatinib-naïve patients. Furthermore, the addition of pembrolizumab may be a viable salvage therapy for patients who have progressed on lenvatinib.

Keyphrases

end stage renal disease
newly diagnosed
ejection fraction
chronic kidney disease
advanced non small cell lung cancer
randomized controlled trial
young adults
patient reported outcomes
open label
combination therapy
patient reported